Psoriatic arthritis (PsA) can sometimes be very difficult to treat, even with modern medicines. Doctors use international guidelines from GRAPPA and EULAR to define which patients should be classified as "complex" or "refractory". However, it was not entirely clear if these two sets of rules identify the exact same patients in real-world clinics.
To make sense of this, we followed 343 patients with PsA to see how well these definitions match up in everyday practice. We found that the EULAR and GRAPPA frameworks agree with each other quite well, proving to be reliable, complementary tools for identifying complex or refractory cases.
Importantly, we looked beyond these definitions to ask: which patients are at the highest risk of developing such complex-to-manage conditions in the first place? We discovered that factors such as early signs of bone erosion in small joints (found using ultrasound) and obesity played a major role. Patients with either of these baseline factors were significantly more likely to develop difficult-to-treat PsA over time.
These findings are an important step toward better, more proactive care in PsA. They suggest that actively managing body weight and using early ultrasound checks to find hidden bone erosion can help doctors tailor treatment plans right from the start, potentially preventing the disease from becoming resistant and protecting joint health for the long term.